Healthcare
Thermo Fisher Scientific Inc.(TMO)
Live Price
Offline$464.61
+0.63% today
1Y Change
+23.06%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $174.37B
- Revenue Growth
- +3.9%
- EPS Growth
- +7.2%
- Dividend Yield
- 0.4%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Thermo Fisher Scientific Inc. (TMO) is a Healthcare stock with a market cap of $174.37B and listed on NYSE. The stock last traded around $464.61 and up 23.1% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +3.9%, EPS growth of +7.2%, a dividend yield of 0.4%. What stands out right now is revenue +3.9%, EPS +7.2%, free cash flow -13.4% with operating margin 17.8% and ROIC 7.3%. The dividend is present but secondary, with a yield around 0.4%. Valuation is more restrained than many high-expectation growth names at P/E 25.4 and price/sales 3.9. Stock Foundry combines TMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.9% vs +7.6% peer median
Operating Margin
Near sector median
+17.8% vs +19.4% peer median
P/E
Below sector median
25.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.9% and EPS at +7.2%, with operating margin around 17.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.6% | +2.6% | -3.7% |
2026 Jan 29, 2026 | +1.9% | -2.3% | -8.4% | -12.0% |
2025 Oct 22, 2025 | +5.3% | +0.8% | -1.6% | +1.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TMO Max Drawdown
-31.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TMO and SPY.
Company Overview
Thermo Fisher Scientific Inc.
New York Stock Exchange
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- Leadership
- Marc N. Casper
- IPO Date
- Mar 17, 1980
- Employees
- 125.0k
- Street Address
- 168 Third Avenue
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 622 1000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 25.4
- EV/EBITDA
- 19.2
- Price/Sales
- 3.9
- Price/Book
- 3.4
Growth
- Revenue
- +3.9%
- EPS
- +7.2%
- Free Cash Flow
- -13.4%
Profitability
- Gross Margin
- 39.4%
- Operating Margin
- 17.8%
- Net Margin
- 15.2%
- ROE
- 13.3%
- ROIC
- 7.3%
Balance Sheet
- Debt/Equity
- 0.83
- Current Ratio
- 1.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.